If the Athersys Stroke Trial is successful (they are announcing the results of their Phase 2A Ischemic Stroke Trial on Sunday, April 19th) they will need a lot more of their Multistem and I would guess that means a lot more business for Neostem. A LOT MORE.....for Japan soon (hopefully).
Once these clients have approved products, Neostem revs should increase significantly.